Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

This is a live story built from multiple sources. It may evolve quickly.

Coverage meter • 1 min window

Back to home Open top source

B bloomberg.com

What’s included

Top recent items from this story.

1 items • 1 unique links

Bloomberg Markets 4 days ago • bloomberg.com

Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He…

Open